Acadia’s Alzheimer’s psychosis drug misses main goal of mid-stage study
Acadia Pharmaceuticals said on Thursday its experimental drug for psychosis associated with Alzheimer’s disease missed the main goal of a mid-stage study, sending the drugmaker’s shares down about 11 per cent.












